# Vivid Dx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vivid-dx

- Industry: Healthcare IT
- Headquarters: Oxford, UK
- Website: www.vivid-dx.com
- Total disclosed funding: $15M
- Latest round: Seed (Jul 28, 2026)
- Investors on record: 3

## About

Founded in 2022 and headquartered in Oxford, UK by Jeff Liu (CTO), Vivid Dx develops advanced diagnostic platforms for rapid pathogen detection. The company has executed 3 deals, with its latest funding round being a Seed round in July 2026, where it raised USD 15.00 million co-led by Cedars-Sinai Accelerator and Jameel Investment Management Company, along with Oxford Sciences Enterprises. The platform aims to revolutionize diagnostic processes for healthcare providers. AS od August 2026, company is led by Keith O'Neill as CEO.
Vivid Dx specializes in the development of advanced diagnostic technologies designed to enhance the speed and accuracy of pathogen identification, specifically targeting sepsis-causing pathogens and antimicrobial resistance. Their core product, a next-generation diagnostic platform, utilizes Raman spectroscopy to analyze the biochemical fingerprints of single cells, facilitating rapid pathogen detection directly from blood samples. This platform is backed by a proprietary Raman spectra database and incorporates advanced artificial intelligence and machine learning algorithms to provide actionable diagnostics. The solutions are positioned primarily for healthcare providers, including hospitals and clinical laboratories, aiming to transform diagnostics and improve patient outcomes. Vivid Dx's products are marketed in regions such as North America and Europe, serving a client base that includes healthcare institutions seeking to optimize their diagnostic processes.
Vivid Dx generates revenue primarily through business-to-business transactions with healthcare providers and clinical laboratories, leveraging subscription models and direct sales of their diagnostic platforms. Clients engage with the company through various partnership agreements, which may include licensing arrangements for the proprietary technology or subscription-based access to the diagnostic platform and associated services. The revenue structure is bolstered by the flagship diagnostic offerings, which aim to significantly reduce the time from infection detection to treatment decision-making. These services are designed to improve outcomes and lower costs, reinforcing the value proposition for healthcare providers. Pricing details for specific products and services are tailored to meet the needs of individual clients, ensuring alignment with the operational requirements of the healthcare institutions they serve.
In July 2026, Vivid Dx raised USD 15.00 million in Seed funding, co-led by returning investor Oxford Sciences Enterprises and new investor Cedars-Sinai Accelerator, with participation from Jameel Investment Management Company and other strategic investors. This funding will support the testing of their platform using patient-derived clinical samples. The company aims to launch upcoming products designed to enhance diagnostic capabilities, with a focus on global expansion into new markets by the end of 2027. Recent preclinical tests showed approximately 99% pathogen identification accuracy, setting a solid foundation for their future growth initiatives.

## Funding rounds

- Seed, Jul 28, 2026, $15M — Oxford Sciences Enterprises, Cedars-Sinai Accelerator, Jameel Investment Management Company

## Investors

- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed
- Cedars-Sinai Accelerator (https://capitalatlas.ai/funds/cedars-sinai-accelerator) — Seed
- Jameel Investment Management Company (https://capitalatlas.ai/funds/jameel-investment-management-company) — Seed